Clinical Trials Browser

Interventional × Alzheimer Disease × 30 days × Clear all

Agnosia, Alzheimer Disease, Pain

NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Phase 2 Active not recruiting

15 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Phase 2 Terminated

11 enrolled

CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT05894954 2026-02-18

EVANTHEA

Phase 3 Completed

73 enrolled

Lymphoid

Alzheimer Disease, Anomia, Dementia, Lymphoma, Follicular, Cognitive Dysfunction

NCT06125951 2026-02-18

XanaMIA

Phase 2/3 Active not recruiting

247 enrolled

Lymphoid

Alzheimer Disease, Dementia, Lymphoma, Follicular

NCT07415629 2026-02-17

Evaluation of a Self-compassion App in People With Cancer: Feasibility, Acceptability and Changes in Well-being

Phase NA Completed

28 enrolled

Emotional Regulation, Alzheimer Disease, Neoplasms

Clinical Trials

PsyMINT

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

EVANTHEA

XanaMIA

Evaluation of a Self-compassion App in People With Cancer: Feasibility, Acceptability and Changes in Well-being